Meeting
2014 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients (pts) with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric): Results of an Australian phase II clinical trial.
Authors
Mustafa Khasraw
Andrew Love Cancer Centre, Geelong, Australia
Mustafa Khasraw , Sally Anne McCowatt , Marc E. Buyse , Zoltan Kerstes , Michael Back , Ganessan Kichenadasse , Helen Wheeler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01124240
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2050^)
DOI
10.1200/jco.2014.32.15_suppl.2050
Abstract #
2050^
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).
First Author: M. Khasraw
Poster
2011 ASCO Annual Meeting
CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
First Author: V. Verschaeve
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2017 ASCO Annual Meeting
Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).
First Author: Bernhard Heinrich